drugset / Trial / NCT00425737

Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants

NCT00425737

Phase 2 Completed 405 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindPrevention

Summary

To assess the efficacy, immune response and safety of the oral live attenuated HRV vaccine (Rotarix) in healthy infants approximately 2 months of age and previously uninfected with human rotavirus

Timeline

Start
2000-08
Primary completion
2001-07
Completion
2001-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotarix Vaccine Oral

Indications